Quarterly Updates14 May 2026, 04:29 pm
Orchid Pharma Monitoring Report for Q4 FY26
AI Summary
Orchid Pharma Ltd has released the Monitoring Agency Report for Quarter IV of financial year 2025-26, ended March 31, 2026. The report, issued by CARE Ratings Limited, pertains to the utilization of proceeds raised through Qualified Institutions Placement (QIP). The monitoring agency declared no deviations from the stated objectives and confirmed that the utilization of funds is in line with the revised allocation schedule. The QIP involved an amount aggregating to ₹400 crores.
Key Highlights
- CARE Ratings Limited issued the Monitoring Agency Report for Q4 FY26.
- The report confirms no deviations from the objectives of the QIP issue.
- Utilization of funds is aligned with the revised allocation schedule.
- The QIP involved an amount aggregating to ₹400 crores.
- Shareholders approved revised allocation of QIP proceeds on September 20, 2025.
Price Impact
More from ORCHIDPHAR